Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies

Overview

Journal Am J Cardiovasc Drugs

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2013 Jan 18

PMID 23325450

Citations 51

Authors

Harold E Bays

Christie M Ballantyne

Rene A Braeckman

William G Stirtan

Paresh N Soni

Affiliations

Soon will be listed here.

Abstract

Background: Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid ethyl ester approved by the US Food and Drug Administration as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. In addition to TG-lowering effects, IPE also reduces non-high-density lipoprotein cholesterol and apolipoprotein B levels without significantly increasing low-density lipoprotein cholesterol (LDL-C) in patients with very high TG levels ≥500 mg/dL (MARINE study) and in patients with well-controlled LDL-C and residually high TG levels 200-500 mg/dL (ANCHOR study). This analysis examined the effect of IPE on inflammatory markers in patients from MARINE and ANCHOR.

Methods: MARINE (N = 229) and ANCHOR (N = 702) were Phase III, double-blind studies that randomized hypertriglyceridemic patients to IPE 4 g/day, 2 g/day, or placebo. This analysis assessed the median placebo-adjusted percentage change from baseline in markers representing various stages of atherosclerotic inflammation such as intercellular adhesion molecule-1 (ICAM-1), oxidized low-density lipoprotein (Ox-LDL), lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP).

Results: Compared to placebo, IPE 4 g/day significantly decreased Ox-LDL (13 %, p < 0.0001, ANCHOR), Lp-PLA(2) (14 %, p < 0.001, MARINE; 19 %, p < 0.0001, ANCHOR), and hsCRP levels (36 %, p < 0.01, MARINE; 22 %, p < 0.001, ANCHOR), but did not significantly change ICAM-1 and IL-6 levels. In the MARINE study, IPE 2 g/day did not significantly change ICAM-1, Ox-LDL, Lp-PLA(2), IL-6, or hsCRP levels. Also, compared to placebo in the ANCHOR study, IPE 2 g/day significantly decreased Lp-PLA(2) levels (8 %, p < 0.0001), but did not significantly change levels of other assessed inflammatory markers.

Conclusion: Compared to placebo, in hypertriglyceridemic patients, IPE 4 g/day significantly decreased Ox-LDL, Lp-PLA(2), and hsCRP levels.

Citing Articles

Erythrocyte Membrane Fluidity and Omega-3 Fatty Acid Intake: Current Outlook and Perspectives for a Novel, Nutritionally Modifiable Cardiovascular Risk Factor.

Capece U, Gugliandolo S, Morciano C, Avolio A, Splendore A, Giuseppe G Nutrients. 2025; 16(24.

PMID: 39770939 PMC: 11676811. DOI: 10.3390/nu16244318.

Compare and Contrast of the Cellular Actions of Related Flavonoids, Apigenin and Chrysin.

Keefe P, Puthanveetil P Nutrients. 2024; 16(23).

PMID: 39683588 PMC: 11644185. DOI: 10.3390/nu16234195.

Potential Beneficial Effects of Crab-Flavored Seafood Intake in Young Rats.

Kadokura K, Tomita T, Suruga K Nutr Metab Insights. 2024; 17:11786388241263717.

PMID: 39483418 PMC: 11526318. DOI: 10.1177/11786388241263717.

Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation.

Sherratt S, Libby P, Dawoud H, Bhatt D, Mason R J Am Heart Assoc. 2024; 13(14):e034076.

PMID: 38958135 PMC: 11292741. DOI: 10.1161/JAHA.123.034076.

Bleeding Risk in Patients Receiving Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Javaid M, Kadhim K, Bawamia B, Cartlidge T, Farag M, Alkhalil M J Am Heart Assoc. 2024; 13(10):e032390.

PMID: 38742535 PMC: 11179820. DOI: 10.1161/JAHA.123.032390.

References

Pedersen M, Koenig W, Christensen J, Schmidt E . The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr. 2008; 48(1):1-5. DOI: 10.1007/s00394-008-0758-z. View

Ballantyne C, Bays H, Kastelein J, Stein E, Isaacsohn J, Braeckman R . Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012; 110(7):984-92. DOI: 10.1016/j.amjcard.2012.05.031. View

Levitan I, Volkov S, Subbaiah P . Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal. 2009; 13(1):39-75. PMC: 2877120. DOI: 10.1089/ars.2009.2733. View

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

Bays H . Adiposopathy is "sick fat" a cardiovascular disease?. J Am Coll Cardiol. 2011; 57(25):2461-73. DOI: 10.1016/j.jacc.2011.02.038. View

Bays H, Ballantyne C, Kastelein J, Isaacsohn J, Braeckman R, Soni P . Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011; 108(5):682-90. DOI: 10.1016/j.amjcard.2011.04.015. View

Chan D, Watts G, Barrett P, Beilin L, Mori T . Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002; 48(6 Pt 1):877-83. View

Nelson T, Hokanson J, Hickey M . Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females. Eur J Nutr. 2010; 50(3):185-93. DOI: 10.1007/s00394-010-0126-7. View

Davidson M, Ballantyne C, Jacobson T, Bittner V, Braun L, Brown A . Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011; 5(5):338-67. DOI: 10.1016/j.jacl.2011.07.005. View

10.

Davidson M, Maki K, Bays H, Carter R, Ballantyne C . Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2011; 3(5):332-40. DOI: 10.1016/j.jacl.2009.08.001. View

11.

Watanabe E, Sobue Y, Sano K, Okuda K, Yamamoto M, Ozaki Y . Eicosapentaenoic acid for the prevention of recurrent atrial fibrillation. Ann Noninvasive Electrocardiol. 2011; 16(4):373-8. PMC: 6931927. DOI: 10.1111/j.1542-474X.2011.00465.x. View

12.

Micallef M, Munro I, Garg M . An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals. Eur J Clin Nutr. 2009; 63(9):1154-6. DOI: 10.1038/ejcn.2009.20. View

13.

Hwang S, Ballantyne C, Sharrett A, Smith L, Davis C, Gotto Jr A . Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1998; 96(12):4219-25. DOI: 10.1161/01.cir.96.12.4219. View

14.

Corson M, Jones P, Davidson M . Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008; 101(12A):41F-50F. DOI: 10.1016/j.amjcard.2008.04.018. View

15.

Mori T, Woodman R, Burke V, Puddey I, Croft K, Beilin L . Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med. 2003; 35(7):772-81. DOI: 10.1016/s0891-5849(03)00407-6. View

16.

Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B . How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009; 102(2):215-22. DOI: 10.1160/TH09-05-0297. View

17.

Glass C, Witztum J . Atherosclerosis. the road ahead. Cell. 2001; 104(4):503-16. DOI: 10.1016/s0092-8674(01)00238-0. View

18.

Kelley D, Siegel D, Fedor D, Adkins Y, Mackey B . DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr. 2009; 139(3):495-501. PMC: 2646223. DOI: 10.3945/jn.108.100354. View

19.

Skulas-Ray A, Kris-Etherton P, Harris W, Vanden Heuvel J, Wagner P, West S . Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr. 2010; 93(2):243-52. PMC: 3138218. DOI: 10.3945/ajcn.110.003871. View

20.

Ballantyne C, Hoogeveen R, Bang H, Coresh J, Folsom A, Chambless L . Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005; 165(21):2479-84. DOI: 10.1001/archinte.165.21.2479. View